Aberrant signalling through the hepatocyte growth factor/ scatter factor receptor Met has been implicated in various aspects of the development of human cancer including the promotion of tumour invasion, angiogenesis and metastasis. Moreover, experimental data indicate that activation of the Met receptor may be involved in cellular resistance towards antineoplastic treatments such as chemotherapy and ionizing radiation. We determined the prevalence and clinical impact of the Met-activating mutation Y1253D in patients with squamous cell cancer of the oropharynx treated by radical radiotherapy. To screen archival tissue for the presence of a low-abundance point mutation, we developed a sensitive screening method using real-time polymerase chain reaction along with peptide nucleic acid-based DNA clamping and melting curve analysis. By this approach, Met Y1253D was detected in tumours of 15 out of 138 patients (10.9%). Both univariate and multivariate survival analysis revealed Met Y1253D to be significantly associated with impaired local tumour control. Our results provide evidence that the Met-activating mutation Y1253D is present in a notable subset of patients with oropharyngeal cancer and indicate that it may interfere with radioresponsiveness of these tumours, supporting the notion of aberrant Met signalling as a potential target for radiosensitization.
Several lines of evidence suggest that the activation of specific receptor tyrosine kinase systems may interfere with ionizing radiation-induced cell death and treatment outcome upon radiotherapy. Apart from the most prominent example in this context, the epidermal growth factor receptor (Raben et al., 2002; Dent et al., 2003) , interference with radioresponsiveness has been reported for the tyrosine kinase-type receptor erbB2 (Pietras et al., 1999) , the insulin-like growth factor I receptor (Turner et al., 1997) and the hepatocyte growth factor/scatter factor receptor Met (Fan et al., 1998; Aebersold et al., 2001) . Activation of Met by its ligand hepatocyte growth factor/scatter factor leads to resistance to cytotoxicity induced by various DNA-damaging agents including ionizing radiation and adriamycin (Fan et al., 1998) . The main mechanisms proposed to account for this cytoprotective effect were stabilization of the antiapoptotic protein Bcl-XL and activation of DNA repair via a phospho-inositol-3 kinase/Aktdependent pathway . Besides this cytoprotective effect, the impact of dysregulated Met tyrosine kinase activity on the development of human cancer and its contribution to an invasive and metastatic phenotype is well established (for a review, see To and Tsao, 1998; Danilkovitch-Miagkova and Zbar, 2002) .
Aberrant Met signalling may occur through different oncogenic mechanisms including overexpression of the receptor and point mutations which all but one appear in the catalytic domain of the receptor, leading to constitutive kinase activity. These mutations were initially reported in hereditary and sporadic cases of papillary renal carcinoma , but later also in hepatocellular carcinoma (Park et al., 1999) and squamous cell carcinomas of the head and neck, where the Met Y1253D mutation has first been identified (Di Renzo et al., 2000; Lorenzato et al., 2002) . Tyrosine 1253 is one of the two residues within the activation loop of the Met protein whose phosphorylation is critical for receptor activation (Rodrigues and Park, 1994; Chiara et al., 2003) . The replacement of the tyrosine 1253 with aspartic acid leads to constitutive activation of the receptor in the absence of a ligand, which is associated with anchorage-independent growth and invasiveness in soft agar (Di Renzo et al., 2000) . In the present retrospective study, we aimed to determine the prevalence and clinical impact of the Met-activating mutation Y1253D (corresponding to T3757G at the genomic level) in patients with squamous cell cancer of the oropharynx treated by radical radiotherapy.
Clinical specimens often contain only a small number of tumour cells within a large background of normal tissue, and in some cases mutations are present only in a subset of the tumour cells. Conventional analysis methods enable to identify the major component or at least a significant amount of a genetic variant such as a somatic point mutation. Nevertheless, the ability to detect low-abundant mutations is of immense importance since cells harbouring these alleles can be associated with a clonal expansion, giving rise to a population with a more aggressive tumour phenotype. By using a combination of an allele-specific amplification technique with TaqMan real-time polymerase chain reaction (PCR), performed on DNA samples obtained from fresh tissue, Di Renzo et al. (2000) have shown that the abundance of the Met Y1253D allele is about 2% in primary tumours of patients with squamous cell carcinoma of the head and neck. In the current study, we aimed at screening DNA from formalin-fixed tissue known to be of significantly lower quality then DNA originating from fresh tissue, adding therefore another considerable difficulty for the detection of low-abundant genetic lesions in such samples.
To screen archival pretherapeutic biopsy material for the presence of Met Y1253D, we have therefore established a novel method using LightCycler s -based real-time PCR in combination with peptide nucleic acid (PNA)-directed clamping. A similar approach was recently described with matrix-assisted laser-desorption/ ionization time-of-flight (MALDI-TOF) as tool for the identification of a K-RAS mutation (Sun et al., 2002) . In our case, we distinguished between amplified wild-type Met and mutated Met Y1253D using melting curve analysis with specific fluorescent hybridization probes. Figure 1 shows the principle of the method as it was established using plasmids carrying the Met wild-type and Y1253D alleles. The full match of the sensor probe to the mutant allele and consecutive mismatch of one base pair to the wild-type allele led to a 7.51C difference in the respective melting temperature (T m ¼ 59.6 or 52.11C, respectively), allowing the specific detection of a mutant peak (Figure 1a and b) . When the two plasmids were present in a 1 : 1 dilution, the two corresponding peaks were detected in one amplification reaction ( Figure 1c ). Decreasing the relative amount of the mutant allele was followed by a reduction and finally a complete disappearance of the mutant peak at a dilution of 2% (Figure 1d and e). However, when the PNA was added to the reaction mixture, the amplification of the wild type allele was completely abolished, whereas the amplification of the mutant allele was restored ( Figure 1f ). These results indicate that our screening approach is able to detect the presence of the Y1253D Met mutation within a background of at least 98% wildtype alleles, corresponding to the low abundance of the Y1253D mutation within primary tumours as described by Di Renzo et al. (2000) . To validate the results obtained with the plasmids, genomic DNA from a tumour sample with confirmed Y1253D mutation (kindly provided by MF Die Renzo) was tested and found to yield exactly the same two melting temperatures (data not shown). The method was then used to screen the pretherapeutic tumour biopsies for the presence of the Y1253D Met mutation. Again, the T m values for Met wild type and, in our positive cases, for the Met Y1253D were equal to the corresponding T m values in the plasmid experiments ( Figure 2 ). The DNA clamping effect by the PNA can be clearly seen in the two presented patient cases: In case 32, the PCR without PNA led to only a tiny mutant peak, which is strongly enlarged in the presence of the PNA; in parallel, the wild-type peak disappeared completely upon DNA clamping (bottom panel). In case 88, the mutant peak was only detectable in the presence of the PNA, clearly demonstrating the capacity of the PNA to allow the detection of point mutations in the background of wild-type alleles where conventional PCR fails. This LightCycler s real-time PCR-based detection approach represents a novel genetic screening method with high throughput which can be used for paraffin-embedded archival material.
Met Y1253D was detected in 15 of 138 pretherapeutic tumour samples (10.9%), indicating its presence in a notable subset of patients with oropharyngeal cancer. Met Y1253D did not correlate with any of the clinicopathological parameters (Table 1) . Assessing the impact of Met Y1253D for treatment outcome, we found a significant decrease of the local tumour control probability by radiotherapy (P ¼ 0.009, log rank; Figure 3 ), the risk ratio for local tumour progression being 2.44 in the presence of the mutation (P ¼ 0.01, Cox regression; Table 2 ). The retrospective property of the study and the relatively low number of Met Y1253D-positive patients limit the statistical power of these results. However, the multivariate analysis proved the effect of Met Y1253D on local tumour progression to be independent from advanced T stage and tobacco exposure, which are known adverse predictive factors in this tumour entity (Table 2) , strongly supporting the validity of the adverse effect exerted by Met Y1253D. From a mechanistic point of view, one may assume that cells carrying the mutant Met allele escape from treatment and overgrow out of the tumour cell population killed by radiotherapy. This assumption is thus very much in line with results from in vitro studies showing resistance to ionizing radiation-induced cell death and enhanced DNA repair capacities upon Met activation by hepatocyte growth factor/scatter factor (Fan et al., 1998 Bowers et al., 2000) . Besides such a direct interference with radiation-induced cell killing, impaired local control in the presence of the Met Y1253D mutation may also be due to increased cellular proliferation, enhanced cell motility and local tumour invasiveness, which have all been described to result from aberrant Met activity in various tumour systems (To and Tsao, 1998; Danilkovitch-Miagkova and Zbar, 2002; Lorenzato et al., 2002) . Irrespective of the underlying mechanism, the results of the present study -along with the previously reported correlation of Met overexpression with local treatment failure ) -add evidence to the notion that aberrant Met signalling may be deleterious for successful radiotherapy.
Since aberrant Met signalling has also been found to be involved in the promotion of distant metastasis (for a review, see To and Tsao, 1998), we assessed whether the presence of the Met Y1253D mutation was associated with the development of systemic spread and/or with overall survival in our study group. As summarized in Table 2 , none of the parameters was significantly linked to the formation of distant metastasis. However, the risk ratio for distant metastasis was considerably enhanced (2.41) in tumours with the Y1253D mutation. The lack of statistical significance may be due to the low number of patients with distant metastasis (14.5%) along with the relatively low number of Met Y1253D-positive tumours. Low statistical power along with uncontrolled imbalances in the context of a retrospective study may also account for the absence of statistical significance of the association of the Met Y1253D mutation with overall survival, the risk ratio for death being 1.29 in the presence of the mutation (Table 2) . 0 -terminal blocked against extension (phosphate) and contained a 5 0 -terminal LightCycler s Red-640 label: LC640-TCATACATGTCTCTGGCAAGACCAp. The sensor probe that was designed to fully match the allele that harbours the T3757G substitution was 3 0 -terminally labelled with fluorescein: 5 0 -GTTGTGTACACTATCGTATTCTTT-F (mutated base is underlined). The wild-type-specific PNA oligomer NH 2 -TACACTATAGTATTCTTT-CONH 2 was present (9 mm) to suppress the amplification of the wild-type allele. Real-time PCR was performed with a LightCycler s (Roche Diagnostics) using FastStart DNA reagents (Roche). PCR was performed as follows: 1 cycle with 10 min at 951C (enzyme activation), 65 cycles with 10 s at 951C (denaturation), 30 s at 571C (annealing of amplification primers and hybridization probes, elongation). Melting analysis was performed by 20 s heating at 951C, 20 s incubation at 401C and slowly heating (0.11C/s) from 40 to 701C and subsequent fluorescence monitoring. Results were processed using the LightCycler s software package (Version 3.5.28). The top panel represents the melting curves; in the graphs of the bottom panel, the ordinate delineates the negative derivative of the fluorescence (F2/F1) per change of temperature; the peaks correspond to the melting temperatures (T m )
Several receptor tyrosine kinases are currently being explored as promising anticancer targets for inhibitory pharmaceutical intervention, among them Met (Maulik et al., 2002) . To individualize treatment strategies, identification of those patients who might benefit most Detection of the Met Y1253D mutation by LightCycler s real-time PCR in combination with PNA-directed DNA clamping and melting curve analysis in two cases of oropharyngeal cancer. DNA was extracted from 10 mm sections of paraffin-embedded pretherapeutic biopsies as previously described (Lindel et al., 2001) . The presence of squamous cell cancer was verified by a pathologist Figure 3 Local progression-free survival according to the presence or absence of the Met Y1253D-activating point mutation. Survival curves were plotted according to the Kaplan-Meier method, the log-rank test being used to determine significant differences (SPSS package Version 10.0.0; SPSS Inc., Chicago, IL, USA). The analysis of local progression-free survival considered both local tumour progression after incomplete remission and local relapse after complete remission as adverse events. Survival was measured from the time when therapy was initiated to the time when the first adverse event was detected or to the date of the last follow-up Met Y1253D in oropharyngeal cancer DM Aebersold et al from such compounds is of paramount importance.
Since Met overexpression per se may lead to aberrant receptor signalling, protein or RNA expression levels may be assessed for treatment stratification. However, tumours with aberrant receptor signalling due to activating somatic point mutations will not be identified by such an approach. A novel sensitive genetic screening tool as we have described might be of great benefit in this regard. This may pertain not only for Met, but also for other signalling proteins that are currently being explored as anticancer targets and that may harbour activating mutations. Cox regressions were calculated to determine the risk ratios of local progression-free survival and overall survival. Logistic regression was performed to calculate the risk ratios for the development of distant metastasis. Qualifying criteria for inclusion in the multivariate analysis were: (a) Po0.1 or (b) risk ratio o0.5 or 42 in the univariate analysis. A backward elimination procedure was then performed to eliminate nonsignificant variables (PX0.1). Statistical analyses were performed using the SPSS package (Version 10.0.0; SPSS Inc., Chicago, IL, USA)
